Protagonist Therapeutics
PTGX
41 hedge funds and large institutions have $144M invested in Protagonist Therapeutics in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 7 closing their positions.
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
56% more capital invested
Capital invested by funds: $91.8M → $144M (+$51.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.08% less ownership
Funds ownership: 48.16% → 48.08% (-0.08%)
5% less funds holding
Funds holding: 43 → 41 (-2)
29% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PC
Polar Capital
London,
United Kingdom
|
+$692K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$540K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$422K |
| 4 |
FSA
Franklin Street Advisors
Chapel Hill,
North Carolina
|
+$231K |
| 5 |
First Manhattan
New York
|
+$230K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$891K |
| 2 |
SAM
Senzar Asset Management
New York
|
-$727K |
| 3 |
GAMA
Graticule Asia Macro Advisors
New York
|
-$328K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$320K |
| 5 |
Renaissance Technologies
New York
|
-$294K |
PTGX Hedge Fund Activity: Q3 2017 in Review
41 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2017, worth a combined $144M — up 56% from $91.8M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of PTGX and 5 opened new positions — a net loss of 2 holders — while 9 trimmed existing stakes and 17 added.
The largest buyer was Polar Capital, adding an estimated $692K. The largest seller was Millennium Management, cutting an estimated $891K.
- 41 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2017, down from 43 in Q2 2017.
- Funds reported $144M of Protagonist Therapeutics stock for Q3 2017, up 56% quarter-over-quarter.
- 5 funds opened new Protagonist Therapeutics positions in Q3 2017 and 7 closed out, a net change of -2 holders.
- The largest Protagonist Therapeutics buyer in Q3 2017 was Polar Capital, an estimated $692K added.
- The largest Protagonist Therapeutics seller in Q3 2017 was Millennium Management, an estimated $891K sold.
Based on aggregated 13F filings for Q3 2017.